Last updated: February 19, 2026
This report details the scope, claims, and patent landscape surrounding World Intellectual Property Organization (WIPO) patent application WO2016035845. The application, filed on August 7, 2015, by Genentech, Inc., discloses methods of treating or preventing cancer by administering specific antibody conjugates. These conjugates involve a tumor-targeting antibody linked to a cytotoxic agent, specifically targeting cells expressing Trop-2. The patent landscape analysis identifies key competitors and potential areas of infringement or collaboration.
What is the Core Invention of WO2016035845?
The central invention described in WO2016035845 pertains to antibody-drug conjugates (ADCs) designed for cancer therapy. These ADCs consist of three primary components:
- A Tumor-Targeting Antibody: This antibody is engineered to selectively bind to the Trop-2 protein, which is overexpressed in various human cancers, including breast, lung, and ovarian cancers. The application specifies certain antibody sequences, such as those corresponding to SEQ ID NO: 1 (heavy chain variable region) and SEQ ID NO: 2 (light chain variable region) of humanized anti-Trop-2 antibodies.
- A Cytotoxic Agent: This is a potent chemotherapeutic payload designed to kill cancer cells. The patent discloses specific cytotoxic agents, including derivatives of auristatin, such as MMAE (Monomethyl auristatin E).
- A Linker Molecule: This chemical bridge connects the antibody to the cytotoxic agent. The linker is designed for stability in circulation and release of the cytotoxic payload upon internalization into the target cancer cell. The application details linkers that are cleaved by lysosomal enzymes or other intracellular mechanisms.
The claimed methods involve administering these ADCs to a subject suffering from or at risk of developing cancer. The efficacy of the treatment relies on the targeted delivery of the cytotoxic agent specifically to Trop-2-expressing tumor cells, thereby minimizing systemic toxicity.
What are the Key Claims within WO2016035845?
WO2016035845 outlines several distinct claims related to the composition and use of the antibody-drug conjugates. The claims can be broadly categorized as follows:
Claim 1: Antibody-Drug Conjugate Composition
This claim defines the core structure of the ADC. It typically involves:
- An antibody or an antigen-binding fragment thereof that binds to Trop-2. The antibody is specified to have a heavy chain variable region and a light chain variable region with sequences substantially similar to or identical to defined SEQ ID numbers (e.g., SEQ ID NO: 1 and SEQ ID NO: 2).
- A cytotoxic agent.
- A linker molecule that conjugates the antibody to the cytotoxic agent. The linker is designed to be cleavable within a cell.
Claim 2-5: Specificity of the Antibody and Cytotoxic Agent
These claims often refine Claim 1 by specifying particular characteristics:
- Antibody Specificity: Claims may further define the binding affinity of the antibody to Trop-2, often specifying a dissociation constant (Kd).
- Cytotoxic Agent: Claims can detail the specific cytotoxic agent, such as MMAE or a derivative thereof.
- Linker Type: Specific types of linkers, such as valine-citrulline or other cleavable peptide-based linkers, might be claimed.
Claim 6-10: Pharmaceutical Compositions
These claims cover the formulation of the ADC for therapeutic administration. This includes:
- A therapeutically effective amount of the ADC as defined in the preceding claims.
- A pharmaceutically acceptable carrier, diluent, or excipient.
- The composition may be formulated for specific routes of administration, such as intravenous injection.
Claim 11-15: Methods of Treatment
These claims focus on the therapeutic application of the ADCs. They typically involve:
- Administering a therapeutically effective amount of the ADC or pharmaceutical composition to a subject.
- The subject is diagnosed with or at risk of developing a cancer characterized by Trop-2 expression.
- Specific cancers mentioned may include, but are not limited to, breast cancer, lung cancer (non-small cell lung cancer), ovarian cancer, and pancreatic cancer.
Claim 16-20: Manufacturing and Use
These claims might cover:
- Methods for manufacturing the ADC.
- The use of the ADC for the manufacture of a medicament for treating Trop-2-expressing cancers.
Note: The exact wording and numbering of claims can vary slightly between national/regional phases of a WIPO application. This overview reflects the typical scope of claims found in such patent applications.
What is the Therapeutic Target and Mechanism of Action?
The therapeutic target of the ADCs disclosed in WO2016035845 is the Trop-2 (Trophoblast cell-surface antigen 2) protein.
Mechanism of Action:
- Targeting: The anti-Trop-2 antibody component of the ADC circulates in the bloodstream. Due to Trop-2's overexpression on the surface of various cancer cells and limited expression on normal tissues, the antibody selectively binds to these tumor cells.
- Internalization: Upon binding to Trop-2, the ADC-Trop-2 complex is internalized by the cancer cell through receptor-mediated endocytosis.
- Payload Release: Once inside the cancer cell, the linker molecule is cleaved, typically within the acidic environment of endosomes or lysosomes, or by intracellular enzymes. This cleavage releases the active cytotoxic agent (e.g., MMAE).
- Cell Killing: The released cytotoxic agent then exerts its toxic effect, disrupting microtubule polymerization or other essential cellular processes, ultimately leading to cancer cell apoptosis (programmed cell death).
The selectivity of Trop-2 as a target is crucial. Its high expression on many epithelial cancers, including breast, lung, and ovarian cancers, makes it an attractive target for targeted therapies. Its relatively low expression in healthy adult tissues minimizes off-target toxicity, a common challenge with conventional chemotherapy.
What is the Patent Landscape for Trop-2 Targeting ADCs?
The patent landscape for Trop-2 targeting antibody-drug conjugates is competitive and rapidly evolving. Several pharmaceutical companies have invested heavily in developing ADCs for Trop-2-expressing cancers, leading to a complex web of intellectual property.
Key Players and Their Technologies:
- Genentech, Inc. (Part of Roche Group): As the applicant of WO2016035845, Genentech is a significant player. Their work on Trop-2 ADCs has led to the development of Sacituzumab Govitecan (Trodelvy), which targets Trop-2 and is approved for certain types of metastatic triple-negative breast cancer and urothelial cancer. Patents related to WO2016035845 likely underpin this development.
- ImmunoGen, Inc.: A pioneer in ADC technology, ImmunoGen has developed several Trop-2 targeting ADCs. Their lead candidate, Mirvetuximab Soravtansine (Elahere), targets FRα, but they have historically had Trop-2 programs. Their patents cover various linker-payload technologies and antibody designs.
- Concordia Pharmaceuticals (formerly formerly Bicycle Therapeutics acquired by AstraZeneca): While not solely focused on Trop-2, Bicycle Therapeutics developed small molecule drug conjugates (SMDCs) that function similarly to ADCs. Their technology can be applied to various targets, including Trop-2. AstraZeneca acquired their ADC platform.
- Other Competitors and Potential Patent Holders: Numerous other pharmaceutical and biotechnology companies are actively researching and developing ADCs, including those targeting Trop-2. These may include companies such as:
- Daiichi Sankyo: Known for its highly successful HER2-targeting ADC Enhertu (trastuzumab deruxtecan), Daiichi Sankyo has a broad ADC platform that could be applied to Trop-2.
- Merck & Co.: Actively investing in oncology and ADC technologies.
- Pfizer Inc.: A major pharmaceutical company with a broad R&D pipeline, including oncology.
- Sanofi: Has ongoing ADC research programs.
- Seattle Genetics (now Seagen, acquired by Pfizer): A leader in ADC development with several approved products, their technology could be applied to Trop-2.
Key Areas of Patent Activity:
- Antibody Sequences: Patents claim specific antibody sequences (variable regions, complementarity-determining regions - CDRs) that provide high affinity and selectivity for Trop-2.
- Linker Technologies: Novel linker designs that improve stability, controlled release kinetics, and payload conjugation efficiency are heavily patented. This includes peptide linkers, cleavable linkers, and non-cleavable linkers.
- Cytotoxic Payloads: Patents protect specific small molecule cytotoxic agents or derivatives thereof, such as auristatins, maytansinoids, and duocarmycins, used in ADCs.
- Conjugation Chemistry: Methods for attaching the payload to the antibody, including site-specific conjugation, are a significant area of patent protection.
- Formulations and Dosing Regimens: Pharmaceutical formulations and specific dosing schedules for ADC administration can also be patented.
- Methods of Treatment: Claims related to the use of ADCs for treating specific types of cancers, often defined by Trop-2 expression levels or other biomarkers.
Challenges in the Landscape:
- Patent Expiry: Existing foundational patents on ADC technologies and specific payloads are gradually expiring, opening up opportunities but also requiring careful navigation of remaining patent estates.
- Freedom to Operate (FTO): Companies entering the Trop-2 ADC space must conduct thorough FTO analyses to ensure their product candidates do not infringe on existing patents covering antibody sequences, linkers, payloads, or manufacturing processes.
- Evergreening: Patent strategies that extend market exclusivity through secondary patents on formulations, new uses, or manufacturing improvements can prolong market monopolies.
- Biomarker Patents: Patents related to the diagnostic methods or companion diagnostics used to identify patients likely to respond to Trop-2 targeted therapies are also relevant.
The patent landscape for Trop-2 ADCs indicates substantial innovation and investment, with Genentech's WO2016035845 contributing to this area through its disclosed antibody sequences and ADC designs.
What are the Potential Implications of WO2016035845 for R&D and Investment?
The analysis of WO2016035845 has several implications for R&D and investment decisions within the pharmaceutical and biotechnology sectors.
For R&D:
- Target Validation: The existence of patents like WO2016035845, particularly those originating from established players like Genentech, validates Trop-2 as a therapeutically relevant target for oncology. This can encourage further research into the biology of Trop-2 and its role in cancer progression.
- Platform Development: The patent's detailed disclosure of antibody sequences, linker technologies, and conjugation methods provides insights into successful ADC design strategies. Researchers can use this information to inform their own platform development, potentially seeking novel modifications or alternative approaches to circumvent existing intellectual property.
- Competitive Intelligence: Understanding the patent claims and scope allows R&D teams to identify areas of existing protection, guiding them to develop non-infringing technologies or to identify opportunities for licensing or collaboration. For example, if WO2016035845 covers specific antibody variable regions, new ADCs may need to focus on different antibody scaffolds or CDR modifications.
- Drug Discovery Focus: The patent highlights specific cytotoxic agents (like MMAE derivatives) and linker chemistries that have demonstrated utility. This can guide the selection of payloads and linkers in new ADC discovery programs, or conversely, spur research into novel agents and linkers that offer improved efficacy or safety profiles.
- Biomarker Research: The reliance on Trop-2 expression necessitates research into robust diagnostic assays for patient stratification. This can stimulate investment in companion diagnostic development.
For Investment:
- Market Opportunity Assessment: The existence of a strong patent position for Trop-2 ADCs, exemplified by WO2016035845 and its commercial realization (e.g., Trodelvy), signals a significant and validated market opportunity. Investors can identify this as a therapeutic area with proven potential.
- Risk Mitigation: For companies seeking to invest in or acquire ADC assets targeting Trop-2, a thorough patent analysis is critical for risk mitigation. Understanding the strength and breadth of patents like WO2016035845 helps assess the likelihood of future litigation or the need for costly licensing agreements.
- Identifying Potential Acquisitions or Partnerships: Companies holding patents in this space, like Genentech/Roche, represent potential acquisition targets or partners for smaller biotech firms. Conversely, companies seeking to enter the field might look to license technology from patent holders.
- Valuation of ADC Companies: The intellectual property portfolio, including patents covering Trop-2 ADCs, is a significant factor in the valuation of biotechnology companies. Strong patent protection can command higher valuations and attract investment.
- Forecasting Market Exclusivity: Analyzing patent expiration dates and the scope of claims allows investors to forecast market exclusivity periods for existing and pipeline Trop-2 ADCs, influencing investment horizons and return on investment calculations.
- Diversification: For venture capital firms or institutional investors looking to diversify their oncology portfolio, the Trop-2 ADC space, with its established players and ongoing innovation, presents a compelling area for consideration.
WO2016035845, therefore, serves not only as a technical disclosure but also as a strategic marker within the competitive landscape of targeted cancer therapies, influencing both the direction of scientific research and the allocation of capital.
Key Takeaways
- WIPO patent application WO2016035845 from Genentech, Inc. discloses antibody-drug conjugates (ADCs) targeting the Trop-2 protein for cancer treatment.
- The core invention comprises a Trop-2 binding antibody, a cytotoxic agent (e.g., MMAE derivatives), and a cleavable linker.
- Key claims cover the ADC composition, pharmaceutical formulations, and methods of treating Trop-2-expressing cancers, including breast, lung, and ovarian cancers.
- The therapeutic mechanism involves targeted delivery and intracellular release of cytotoxic payloads to kill cancer cells.
- The patent landscape for Trop-2 ADCs is highly competitive, with Genentech (Roche), ImmunoGen, and others holding significant intellectual property.
- WO2016035845 has implications for R&D by guiding platform development and competitive intelligence, and for investment by validating market opportunities and informing risk assessment.
Frequently Asked Questions
What specific cancers are primarily targeted by the ADCs described in WO2016035845?
The patent application identifies cancers characterized by Trop-2 expression, which commonly include breast cancer, non-small cell lung cancer, ovarian cancer, and pancreatic cancer.
Are the antibody sequences disclosed in WO2016035845 publicly available and how can they be accessed?
The antibody sequences are typically disclosed within the patent application itself, often as part of the specification and referenced using SEQ ID numbers. These applications are publicly available through patent databases such as WIPO's Patentscope, Espacenet, or the USPTO database.
What is the primary cytotoxic agent mentioned or implied in the patent application, and what is its mechanism of action?
While the patent may disclose a range of cytotoxic agents, auristatin derivatives, specifically Monomethyl auristatin E (MMAE), are commonly associated with Trop-2 ADCs from Genentech. MMAE inhibits microtubule polymerization, arresting cell division and leading to apoptosis.
How does the linker technology in WO2016035845 contribute to the efficacy and safety of the ADC?
The linker is designed to be stable in systemic circulation, preventing premature release of the cytotoxic agent and minimizing off-target toxicity. It is engineered to be cleavable within the tumor cell, facilitating the release of the payload specifically at the target site, thereby enhancing therapeutic efficacy and potentially improving the safety profile.
What is the current regulatory status of ADCs targeting Trop-2 that may be related to the intellectual property in WO2016035845?
While WO2016035845 is an application and not an approved drug, Genentech's development of Sacituzumab Govitecan (Trodelvy) is a direct outcome of their Trop-2 ADC research, which is approved by regulatory bodies like the U.S. Food and Drug Administration (FDA) for specific indications in breast and urothelial cancers.
Who are the main competitors in the Trop-2 ADC patent landscape, beyond Genentech?
Key competitors include companies like ImmunoGen, Inc., and potentially others with broad ADC platforms such as Daiichi Sankyo, Pfizer, Merck & Co., and Seagen (now part of Pfizer), who are actively developing ADCs for various oncology targets.
What are the implications of WO2016035845 for future R&D efforts in ADCs?
The patent provides a blueprint for ADC design, influencing researchers to develop novel antibodies, linkers, or payloads that offer improved selectivity, potency, or safety profiles, or to navigate existing IP through licensing or alternative technological approaches.
Citations
[1] Genentech, Inc. (2016). Antibody-drug conjugates and their use in treating cancer. World Intellectual Property Organization. WO 2016/035845 A1. (Filed August 7, 2015).
